KLK3 and metastatic neoplasm: Although the widespread use of prostate-specific antigen (PSA) testing has reduced the incidence of metastatic prostate cancer (mPCa) (4), 6% of PCa patients in the United States and 15.8% in the Netherlands still have metastatic disease at diagnosis (3, 5).